EcoDrugPlus

Platelet-Activating Factor Acetylhydrolase-Like

Ensembl ID : ENSOTSG00005029759
Gene Symbol: LOC112245385
3 Cross references
196 Possible Orthologues:

Platelet-Activating Factor Acetylhydrolase-Like

Ensembl ID : ENSOTSG00005001621
Gene Symbol: LOC112245385
3 Cross references
196 Possible Orthologues:

Platelet-Derived Growth Factor Receptor Alpha-Like

Ensembl ID : ENSOTSG00005017035
Gene Symbol: LOC112251205
3 Cross references
197 Possible Orthologues:

Platelet-Derived Growth Factor Receptor Alpha-Like

Ensembl ID : ENSOTSG00005029659
Gene Symbol: LOC112251129
3 Cross references
197 Possible Orthologues:

Platelet-Derived Growth Factor Receptor Beta-Like

Ensembl ID : ENSOTSG00005030813
Gene Symbol: LOC112256098
3 Cross references
192 Possible Orthologues:

Platelet-Derived Growth Factor Receptor, Beta Polypeptide

Ensembl ID : ENSOTSG00005022225
Gene Symbol: PDGFRB
1 Cross references
192 Possible Orthologues:

Poly (Adp-Ribose) Polymerase 2

Ensembl ID : ENSOTSG00005037243
Gene Symbol: PARP2
1 Cross references
185 Possible Orthologues:

Poly (Adp-Ribose) Polymerase Family, Member 3

Ensembl ID : ENSOTSG00005014431
Gene Symbol: PARP3
1 Cross references
192 Possible Orthologues:

Poly [Adp-Ribose] Polymerase 3-Like

Ensembl ID : ENSOTSG00005019548
Gene Symbol: LOC112254645
3 Cross references
194 Possible Orthologues:

Poly(Adp-Ribose) Polymerase 1

Ensembl ID : ENSOTSG00005023055
Gene Symbol: PARP1
3 Cross references
207 Possible Orthologues:

Porcupine O-Acyltransferase

Ensembl ID : ENSOTSG00005035751
Gene Symbol: PORCN
1 Cross references
186 Possible Orthologues:

Porcupine O-Acyltransferase

Ensembl ID : ENSOTSG00005034922
Gene Symbol: PORCN
1 Cross references
186 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).